Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

被引：0
|
作者：
Kensei Tobinai
Toshiki Uchida
Noriko Fukuhara
Tomoaki Nishikawa
机构：
[1] National Cancer Center Hospital,Department of Hematology
[2] Japanese Red Cross Nagoya Daini Hospital,undefined
[3] Tohoku University Hospital,undefined
[4] Janssen Pharmaceutical K.K.,undefined
来源：
International Journal of Hematology | 2019年 / 109卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 368
页数：2
相关论文
共 50 条
  • [21] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
    Koji Kato
    Shinichi Makita
    Hideki Goto
    Junya Kanda
    Nobuharu Fujii
    Kazuyuki Shimada
    Koichi Akashi
    Koji Izutsu
    Takanori Teshima
    Natsuko Fukuda
    Tokuhito Sumitani
    Hiroyuki Sumi
    Shinji Shimizu
    Yasuyuki Kakurai
    Kenji Yoshikawa
    Kensei Tobinai
    Noriko Usui
    Kiyohiko Hatake
    International Journal of Clinical Oncology, 2022, 27 : 213 - 223
  • [22] Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan
    Munakata, Wataru
    Ando, Kiyoshi
    Hatake, Kiyohiko
    Fukuhara, Noriko
    Kinoshita, Tomohiro
    Fukuhara, Suguru
    Shirasugi, Yukari
    Yokoyama, Masahiro
    Ichikawa, Satoshi
    Ohmachi, Ken
    Gion, Naokazu
    Aoi, Arata
    Tobinai, Kensei
    CANCER SCIENCE, 2019, 110 (05) : 1686 - 1694
  • [23] Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
    Hamlin, Paul A.
    Flinn, Ian W.
    Wagner-Johnston, Nina
    Burger, Jan A.
    Coffey, Greg P.
    Conley, Pamela B.
    Michelson, Glenn
    Leeds, Janet M.
    Der, Kenneth
    Kim, Yvonne
    Sabalvaro-Torres, Alice
    Birrell, Matt
    Pandey, Anjali
    Curnutte, John T.
    Patel, Manish R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (04) : E90 - E93
  • [24] A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies
    Woyach, Jennifer
    Tees, Michael
    Mota, Nancy
    Brown, Gladys
    Kim, Su Young
    Patel, Manish R.
    CANCER RESEARCH, 2024, 84 (07)
  • [25] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [26] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [27] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Hideki Goto
    Satoshi Ito
    Masahiro Kizaki
    Masaki Yamaguchi
    Noriko Fukuhara
    Koji Kato
    Toko Saito
    Yasuhito Terui
    Sumiko Okubo
    Tomomi Soshin
    Jiewei Zeng
    Hideyuki Honda
    Mohamed Badawi
    Jeremy A. Ross
    Koji Izutsu
    International Journal of Clinical Oncology, 2024, 29 : 232 - 240
  • [28] A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies
    Harb, Wael
    Lakhani, Nehal J.
    Messmann, Richard
    Klencke, Barbara
    Al-Katib, Ayad M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : 823 - 830
  • [29] Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn K.
    Behnia, Sanaz
    Wu, Qian Vicky
    Voutsinas, Jenna M.
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather A.
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda A.
    Smith, Stephen D.
    Gopal, Ajay K.
    BLOOD, 2019, 134
  • [30] Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Uchida, Toshiki
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Mori, Masakazu
    Terui, Yasuhito
    Yokoyama, Masahiro
    Hotta, Tomomitsu
    CANCER SCIENCE, 2013, 104 (01) : 105 - 110
12345